Evaluation of prostate cancer prevalence in Iranian male population with increased PSA level, a one center experience

Cancer Management and Research

Volumn 3, Issue 1, 2011, Pages 227-231

  Moslemi, Mohammad Kazem ^a   Lotfi, Fariborz ^b   Tahvildar, Seyed Ali ^c  

^a QOM UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b KERMANSHAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c ISLAMIC AZAD UNIVERSITY   (Iran)

Author keywords

Benign prostate hyperplasia; Bph; Digital rectal examination; Dre; Lower urinary tract symptoms; LUTS; PCa; Prostate biopsy; Prostate carcinoma; Prostate specific antigen

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DIGITAL RECTAL EXAMINATION; DYSURIA; EARLY DIAGNOSIS; HUMAN; INCIDENCE; IRAN; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; NOCTURIA; POPULATION RESEARCH; PREVALENCE; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATITIS; TRANSRECTAL ULTRASONOGRAPHY; URINARY FREQUENCY;

EID: 80955136911     PISSN: None     EISSN: 11791322     Source Type: Journal    
DOI: 10.2147/cmar.s18147     Document Type: Article

References (35)

1. Howe HL, Wingo PA, Thun MJ, et al. Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends. J Natl Cancer Cancer Inst. 2001;93: 824-842.
2. Hosseini M, Seyed Alinaghi S, Ahmoudi M, McFarland W. A casecontrol study of risk factors for prostate cancer in Iran. Acta Med Iran. 2010;48(1):61-66.
3. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostae. N Engl J Med. 1987;317:909-916.
4. Lin K, Lipsitz R, Miller T, Janakiraman S. Benefits and harms of prostate-specific antigen screening for prostate cancer: an evidence update for the US Preventive Services Task Force. Ann Intern Med. 2008;149(3):192-199.
5. Oesterling JE. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol. 1991;145:907-923.
6. Moslemi MK, Abedin Zadeh MA. A modified technique of simple suprapubic prostatechomy: no bladder drainage and no bladder neck or hemostatic surfaces. Urol J. 2010;7(1):51-55.
7. Benson MC, Whang IS, Pantuck A, et al. Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. J Urol. 1992;147:815-816.
8. Catalona WJ, Richie JP, Ahmann FR, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol. 1994;151:1283-1290.
9. Park HK, Hong SK, Byun SS, Lee SE. Comparison of the rate of detecting prostate cancer and the pathologic characteristics of the patients with a serum PSA level in the range of 3.0 to 4.0 ng/mL and the patients with a serum PSA level in the range 4.1 to 10.0 ng/mL. Korean J Urol. 2006;47:358-361.
10. Cho JM, Lee SW, Kang JY, Yoo TK. Safety and efficacy of combined transrectal ultrasound-guided prostate needle biopsy and transurethral resection of the prostate. Korean J Urol. 2010;51(2):101-105.
11. Rommel FM, Agusta VE, Breslin JA, et al. The use of prostate specific antigen and prostate specific antigen density in the diagnosis of prostate cancer in a community based urology practice. J Urol. 1994; 151:88-93.
12. Dadkhah F, Safarinejad MR, Amini E, Lashay AR, Baghayee A. Utility of prostate specific antigen density and free to total prostate specific antigen ratio for detecting prostate cancer in Iranian men: a prospective study of 187 cases. Curr Urol. 2010;4:1-5.
13. Hosseini SY, Moharramzadeh M, Ghadian AR, Hooshyar H, Lashay AR, Safarinejad MR. Population-based screening for prostate cancer by measuring total serum prostate-specific antigen in Iran. Int J Urol. 2007;14:406-411.
14. Mostofi FK, Sesterhenn I, Sobin LH. Histological typing of prostate tumors. In: Mostofi FK. International Histological Classification of Tumors No. 22. Geneva: World Health Organization; 1980: 1-26.
15. DF. Veterans Administration Cooperative Urological Research Group. Histologic grading and staging of prostatic carcinoma. In: Tannenbaum M, editor. Urologic Pathology: the prostate. Philadelphia: Lea & Febiger; 1977:171-198.
16. Ghafoori M, Varedi P, Hosseini SJ, Asgari M, Shakiba M. Value of prostate-specific antigen and prostate-specific antigen density in detection of prostate cancer in an Iranian population of men. Urol J. 2009;6(3):182-188.
17. Mousavi SM. Toward prostate cancer early detection in Iran. Asian Pac J Cancer Prev. 2009;10(3):413-418.
18. Mohagheghi MA, Mosavi-Jarrahi R, Malekzadeh R, Parkin M. Cancer incidence in Tehran metropolis: the first report from the Tehran Population-based Cancer Registry, 1998-2001. Arch Iran Med. 2009; 12(1):15-23.
19. Mousavi SM, Gouya MM, Ramazani R, Davanlou M, Hajsadeghi N, Seddighi Z. Cancer incidence and mortality in Iran. Ann Oncol. 2009; 20(3):556-563.
20. Akbari ME, Hosseini SJ, Rezaee A, Hosseini MM, Rezaee I, Sheikhvatan M. Incidence of genitourinary cancers in the Islamic Republic of Iran: a survey in 2005. Asian Pac J Cancer Prev. 2008;9(4): 549-552.
21. Sadjadi A, Malekzadeh R, Derakhshan MH, et al. Cancer occurrence in Ardabil. Results of a population-based cancer registry from Iran. Int J Cancer. 2003;107:113-118.
22. Safarinejad MR. Population-based screening for prostate cancer by measuring free and total serum prostate-specific antigen in Iran. Ann Oncol. 2006;17:1166-1171.
23. Khezri AA, Shirazi M, Ayatollahi SM, et al. Age specific reference levels of serum prostate-specific antigen, prostate volume and prostate specific antigen density in healthy Iranian men. Iran J Immunol. 2009; 6(1):40-48.
24. Mehrabi S, Ghafarian Shirazi H, Rasti M, Bayat B. Analysis of serum prostate-specific antigen levels in men aged 40 years and older in Yasuj, Iran. Urol J. 2005;2:189-192.
25. Amirrasouli H, Kazerouni F, Sanadizade J, et al. Accurate cut-off point for free to total prostate-specific antigen ratio used to improve differentiation of prostate cancer from benign prostate hyperplasia in Iranian population. Urol J. 2010;10;7(2):99-104.
26. Catalona WJ, Partin AW, Slawin KM, et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA. 1998;279:1542-1547.
27. Kang SH, Bae JH, Park HS, et al. Prostate-specific antigen adjusted for the transition zone volume as a second screening test: a prospective study of 248 cases. Int J Urol. 2006;13:910-914.
28. Yamamoto S, Kin U, Nakamura K, et al. Transperineal ultrasoundguided 12-core systematic biopsy of the prostate for patients with a prostate specific antigen level of 2.5-20 ng/mL in Japan. Int J Clin Oncol. 2005; 10:117-121.
29. Okihara K, Kitamura K, Okada K, Mikami K, Ukimura O, Miki T. Ten year trend in prostate cancer screening with high prostate specific antigen exposure rate in Japan. Int J Urol. 2008;15:156-160.
30. Sheikh M, Al-Saeed O, Kehinde EO, Sinan, Anim JT, Ali Y. Utility of volume adjusted prostate specific antigen density in the diagnosis of prostate cancer in Arab men. Int Urol Nephrol. 2005;37:721-726.
31. Lam JS, Cheung YK, Benson MC, Goluboff ET. Comparison of the predictive accuracy of serum prostate specific antigen levels and prostate specific antigen density in the detection of prostate cancer in Hispanic- American and white men. J Urol. 2003;170:451-456.
32. Hamashima C, Nakayama T, Sagawa M, Saito H, Sobue T. The Japanese guidelines for prostate cancer screening. Jpn J Clin Oncol. 2009;39(6): 339-351.
33. van Vugt HA, Bangma CH, Roobol MJ. Should prostate-specific antigen screening be offered to asymptomatic men? Expert Rev Anticancer Ther. 2010;10(7):1043-1053.
34. Hua LX, Qiao D, Song NH, et al. Clinical value of prostate specific antigen screening in early detection of prostate cancer. Zhonghua Zhong Liu Za Zhi. 2009;31(9):705-709.
35. Gohji K, Nomi M, Egawa S, et al. Detection of prostate carcinoma using prostate specific antigen, its density, and the density of the transition zone in Japanese men with intermediate serum prostate specific antigen concentrations. Cancer. 1997;79(10):1969-1976.